FREENOME is going public via SPAC merger with Perceptive Capital Solutions. They’re building blood-based cancer detection tests, with first-gen colorectal screening launching as SimpleScreen in 2026.

The deal is expected to generate roughly $330M, including a $240M PIPE led by Perceptive Advisors and RA Capital. Bain Capital Life Sciences is also participating. SimpleScreen commercialization deals are already in place with Exact Sciences and Roche. But they’re entering a crowded field — Guardant’s Shield won FDA approval in 2024. Redemption risk is real: the SPAC trust holds only $90M. If shareholders walk, the capital picture changes fast. Bottom line: a well-funded liquid biopsy play with strong backers and partnerships, but 2026 launch timing leaves room for competitors to tighten their grip.

The deal is expected to generate roughly $330M, including a $240M PIPE led by Perceptive Advisors and RA Capital. Bain Capital Life Sciences is also participating.